Pathological response of gastrointestinal stromal tumour to imatinib treatment correlates with tumour KIT mutational status in individual tumour clones [9]

Histopathology

Volumn 49, Issue 1, 2006, Pages 99-100

  Loughrey, M B ^a   Beshay, V ^a   Dobrovic, A ^a   Zalcberg, J ^a   Waring, P M ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; STEM CELL FACTOR RECEPTOR;

ADULT; CASE REPORT; DRUG TARGETING; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; METASTASIS; PRIORITY JOURNAL; PROTO ONCOGENE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA, NEOPLASM; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MIDDLE AGED; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES;

EID: 33745657428     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2006.02336.x     Document Type: Letter

References (8)

1. Abdulkader I, Cameselle-Teijeiro J, Forteza J. Pathological changes related to Imatinib treatment in a patient with a metastatic gastrointestinal stromal tumour. Histopathology 2005; 46; 470-472.
2. Colecchia M, Diment J. Images in pathology. Morphologic features of response to Gleevec (Imatinib) treatment of GIST. Int. J. Surg. Pathol. 2003; 11; 119.
3. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001; 344; 1052-1056.
4. Hogenauer C, Langner C, Lipp RW, Hofler G, Krejs GJ, Hinterleitner TA. Complete remission of a metastatic gastrointestinal stromal tumour with the tyrosine kinase inhibitor imatinib (STI 571): effect of low dosage in an advanced tumour with exon 11 mutation. Eur. J. Gastroenterol. Hepatol. 2003; 15; 323-327.
5. Heinrich MC, Corless CL, Demetri GD et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003; 21; 4342-4349.
6. Debiec-Rychter M, Dumez H, Judson I et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 2004; 40; 689-695.
7. Debiec-Rychter M, Cools J, Dumez H et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005; 128; 270-279.
8. Fletcher JA, Corless CL, Dimitrijevic S. Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc. Am. Soc. Clin. Oncol. 2003; 22 (Abstr. 3275); 815.